


GAU 1633
#5



Docket No. 50875-F-PCT-US/JPW/SHS

RECEIVED

In re application of: Graham P. Allaway, et al.

APR 28 2000

Serial No.: 09/460,216

Filed: December 13, 1999

Art Unit: 1633 TECH CENTER 1600/2900

For: METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

April 24, 2000

S I R:

Transmitted herewith is an amendment to the above-identified application.

Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

X No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
							SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	4	-	* 20	=	*** 0	x	9	18	=	0 0
Indepen- dent Claims	1	-	** 3	=	*** 0	x	39	78	=	0 0
Multiple Dependent Claims(s) Presented Yes <u>X</u> No							130	260		0 0
For First Time:							TOTAL ADDITIONAL \$ 0 FEE			

- *If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
- **If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.
- ***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicants: Graham P. Allaway, et al.
Serial No.: 09/460,216
Filed: December 13, 1999

RECEIVED

APR 28 2000

Amendment Transmittal Letter
Page 2

TECH CENTER 1600/2900

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

____ Please charge Deposit Account No. _____
in the amount of \$ _____.

____ A check in the amount of \$ _____ is enclosed.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

X Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.


X Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


John P. White
Reg. No. 28,678

4/24/00

Date



Dkt. 50875-F-PCT-US/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Graham P. Allaway, et al.
Serial No.: 09/460,216
Filed : December 13, 1999 Art Unit: 1633
For : METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

1185 Avenue of the Americas
New York, New York 10036
April 24, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**AMENDMENT IN RESPONSE TO FEBRUARY 24, 2000
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES AND APRIL 13, 2000 TELEPHONE CONFERENCE**

This Amendment is submitted in response to the February 24, 2000 Notice To Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the February 24, 2000 Notice To Comply is attached hereto as **Exhibit A**. A response to the February 24, 2000 Notice is due April 24, 2000. Accordingly, this Communication is being timely filed.

Please amend the subject application as follows:

In the claims:

Please amend claims 61-64 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows.

--61. (Amended) A method of inhibiting HIV-1 infection of CD4+ cells which comprises contacting CD4+ cells with a non-chemokine [peptidyl] agent capable of binding to a chemokine receptor in an amount and under conditions